
    
      Following unblinding at the end of the double-blind period and demonstration of a
      statistically significant advantage of enzalutamide over placebo when added to ADT as
      assessed by the primary endpoint of rPFS, subjects were eligible to transition to an
      open-label portion of the study.
    
  